ACC Scientific Session - American College of Cardiology Scientific Session

Mark Svet, MD, is the lead study author on a sub-analysis of the VOYAGER PAD study evaluating data on the use of rivaroxaban in patients with peripheral artery disease (PAD) and chronic kidney disease (CKD).

Multiple approaches can be taken to optimize medical therapy in patients with PAD.

Pharmacy Times spoke with Dipti Itchhaporia, MD, the 70th president of the American College of Cardiology (ACC).

Despite the approval of exciting new therapies for heart failure, there are still some challenges that need to be addressed to improve patient outcomes.

Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment.

Results of the phase 3 VOYAGER PAD clinical trial show rivaroxaban (Xarelto; Janssen Pharmaceutical Companies) plus aspirin lowers severe vascular events in patients with peripheral arterial disease after lower-extremity revascularization.

Session explores data from both the SCORED trial of sotagliflozin and the REVERSE-IT trial investigating bentracimab to reverse the antiplatelet effects of ticagrelor.

Health care professionals need to meet their patients at their health level and find a diet and medication regimen that works for them to best reduce the risk of cardiovascular events.

Pharmacy Times spoke with Craig Granowitz, MD, PhD, chief medical officer at Lexicon Pharmaceuticals, to learn more about sotagliflozin and new data being presented at the American College of Cardiology 2022 Scientific Sessions.

Pharmacy Times spoke with Orly Vardeny, PharmD, MS, a core investigator at the Center for Care Delivery and Outcomes Research in the US Department of Veterans Affairs, about pharmacists’ roles in managing pharmacotherapy disparities.

Lowering salt intake was not found to reduce visits to the emergency department, however, there were improvements in quality of life.

Milind Desai, MD, national principal investigator of the VALOR-HCM trial, discussed new results presented at the American College of Cardiology 2022 Scientific Sessions.

Analysis is based on 2018 hospitalization rates of patients with cardiovascular disease in New Jersey.

Measurements may not be accurate in those with darker tones, according to analysis to be presented at the American College of Cardiology’s 71st Annual Scientific Session.

They are also at greater risk of death than men when undergoing cardiac procedures, a new analysis shows.

Analysis to be presented at the American College of Cardiology’s 71st Annual Scientific Session is based on the health records of 495,386 patients.

At the American College of Cardiology Scientific Session, a study of prescriptions for PCSK9 inhibitors confirms what doctors say about trying to get their patients access to the cholesterol drug.

A double dose of inclisiran reduced LDL cholesterol up to 52.6%.

Discrepancies found when comparing real-world findings to clinical trial findings.

Preliminary trial finds moderate-intensity exercise does not increase adverse events in this patient population.

Researchers sought to change the volume of fatty deposits in a coronary artery that was at least 30% blocked.

Study compares common treatment options to prevent recurrent venous thromboembolism.

Complications associated with left main bifurcation can impact stent choice.

A multi-faceted screening approach could prevent sudden cardiac deaths in young athletes.

Including warning labels may improve healthy eating habits.

Americans admitted to the hospital for heart failure have a 6% higher risk of dying than patients admitted in the spring.

Treatments have only increased 10% in hospitals nationwide over the past decade.

A self-expanding transcatheter aortic valve replacement (TAVR) procedure was just as effective as surgery in intermediate risk patients.

The Patient Navigator Program reduced readmission for heart attack or heart failure patients by 81.3%.